{"id":"NCT00311402","sponsor":"Boehringer Ingelheim","briefTitle":"JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme","officialTitle":"JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2009-03","completion":null,"firstPosted":"2006-04-06","resultsPosted":"2010-03-11","lastUpdate":"2014-02-14"},"enrollment":1295,"design":{"allocation":null,"model":"PARALLEL","masking":null,"primaryPurpose":"PREVENTION"},"conditions":["Cerebrovascular Accident"],"interventions":[{"type":"DRUG","name":"Aggrenox capsule","otherNames":[]},{"type":"OTHER","name":"Acetylsalicylic Acid (ASA)","otherNames":[]}],"arms":[{"label":"Aggrenox Capsule","type":"OTHER"},{"label":"Acetylsalicylic Acid (ASA) 81 mg Tablet","type":"OTHER"}],"summary":"Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily","primaryOutcome":{"measure":"Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal)","timeFrame":"Up to 124 weeks","effectByArm":[{"arm":"Aggrenox Capsule","deltaMin":45,"sd":null},{"arm":"Acetylsalicylic Acid (ASA) 81 mg Tablet","deltaMin":32,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.097"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":151,"countries":["Japan"]},"refs":{"pmids":["21502757"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":178,"n":655},"commonTop":["Nasopharyngitis","Headache","Fall","Diarrhoea","Back pain"]}}